Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Trial Profile

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 May 2015

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Heart failure; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms PITCH-HF
  • Most Recent Events

    • 19 Feb 2014 Status changed from active, no longer recruiting to discontinued according to ClinicalTrials.gov record.
    • 26 Jan 2014 New source identified and integrated (Oregon Health and Science University Institutional Review Board).
    • 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top